Drug Trial Radar · NCT02351960
Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease
Last checked: Nov 20, 2026Latest source record: Oct 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Mar 19, 2015
Primary completion
Jun 22, 2016
Study completion Jul 13, 2016
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness of symptom control in gastroesophageal reflux disease (GERD) participants following treatment with dexlansoprazole.
Conditions
- Gastroesophageal Reflux Disease
Interventions
DexlansoprazoleDrug
Dexlansoprazole capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of 24-Hour Heartburn and Acid Regurgitation-Free Days in Non-Erosive Reflux Disease (NERD) ParticipantsTime frame: Up to Week 4
- Percentage of 24-Hour Heartburn and Acid Regurgitation-Free Days in Erosive Esophagitis (EE) ParticipantsTime frame: Up to Week 8
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Shatin, New Territories, Hong Kong
Site not named
Gyeonggi-do, South Korea
Site not named
Gyeonggi-do, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Kaoshiung, Taiwan
Site not named
Taichung, Taiwan
Site not named
Tainan, Taiwan
Site not named
Taipei, Taiwan
Site not named
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.